PIM1 and rheumatoid arthritis: Amongst RA patients who experience good therapeutic responses to the anti-IL-6 receptor monoclonal antibody tocilizumab, concurrent down-regulation of STAT3-regulated genes by CD4+ T cells has been eloquently demonstrated—including that of BCL3, PIM1 and SOCS3 [26].